Frontiers Lu-177-PSMA dosimetry for kidneys and tumors based on SPECT images at two imaging time points

Lutetium-177 prostate-specific membrane antigen (PSMA

Frontiers Lu-177-PSMA dosimetry for kidneys and tumors based on

Preclinical Dosimetry, Imaging, and Targeted Radionuclide Therapy

Cancers, Free Full-Text

Lu-177-PSMA dosimetry based on two-imaging-time-point

Development of 177Lu-scFvD2B as a Potential Immunotheranostic

Low cost, high temporal resolution optical fiber-based γ-photon

Cancers, Free Full-Text

Radiation Dosimetry in 177Lu-PSMA-617 Therapy - ScienceDirect